bluebird bio, Inc.
Index- P/E- EPS (ttm)-8.01 Insider Own1.50% Shs Outstand73.69M Perf Week-0.59%
Market Cap225.96M Forward P/E- EPS next Y-2.45 Insider Trans-2.35% Shs Float70.54M Perf Month-20.80%
Income-563.30M PEG- EPS next Q-1.23 Inst Own90.80% Short Float17.22% Perf Quarter-45.62%
Sales4.70M P/S48.08 EPS this Y9.50% Inst Trans8.08% Short Ratio5.09 Perf Half Y-70.38%
Book/sh3.57 P/B0.94 EPS next Y49.20% ROA- Target Price7.67 Perf Year-83.15%
Cash/sh3.14 P/C1.07 EPS next 5Y- ROE- 52W Range3.11 - 23.04 Perf YTD-66.47%
Dividend- P/FCF- EPS past 5Y-2.90% ROI-157.90% 52W High-85.46% Beta1.63
Dividend %- Quick Ratio- Sales past 5Y-9.90% Gross Margin- 52W Low7.89% ATR0.36
Employees518 Current Ratio1.80 Sales Q/Q111.10% Oper. Margin- RSI (14)41.55 Volatility6.86% 9.77%
OptionableYes Debt/Eq0.00 EPS Q/Q8.60% Profit Margin- Rel Volume0.84 Prev Close3.33
ShortableYes LT Debt/Eq0.00 EarningsMay 09 AMC Payout- Avg Volume2.39M Price3.35
Recom3.00 SMA20-10.45% SMA50-22.90% SMA200-62.74% Volume1,993,715 Change0.60%
Apr-06-22Downgrade Cowen Outperform → Market Perform
Mar-07-22Downgrade Barclays Equal Weight → Underweight $4
Nov-08-21Reiterated Wells Fargo Equal Weight $25 → $16
Nov-08-21Reiterated Wedbush Neutral $22 → $11
Nov-08-21Reiterated RBC Capital Mkts Sector Perform $26 → $14
Nov-08-21Reiterated Canaccord Genuity Hold $20 → $15
Nov-08-21Reiterated Barclays Equal Weight $20 → $13
Nov-08-21Downgrade Morgan Stanley Equal-Weight → Underweight $11
Nov-08-21Downgrade Goldman Neutral → Sell $23 → $10
Aug-10-21Resumed William Blair Mkt Perform
Aug-10-21Downgrade Wells Fargo Overweight → Equal Weight $60 → $25
Aug-10-21Downgrade Goldman Buy → Neutral $63 → $23
Aug-10-21Downgrade Canaccord Genuity Buy → Hold
Aug-09-21Downgrade SVB Leerink Outperform → Mkt Perform
Jul-01-21Downgrade Berenberg Buy → Hold $35
Mar-10-21Upgrade Mizuho Neutral → Buy $34 → $69
Feb-17-21Downgrade JP Morgan Overweight → Neutral $76 → $39
Feb-16-21Downgrade William Blair Outperform → Mkt Perform
Feb-16-21Downgrade Wedbush Outperform → Neutral
Feb-16-21Downgrade BofA Securities Buy → Neutral
May-13-22 10:32AM  
May-09-22 06:25PM  
Apr-27-22 03:03PM  
Apr-22-22 03:29PM  
Apr-17-22 11:15AM  
Apr-15-22 11:30AM  
Apr-08-22 06:57AM  
Apr-06-22 12:36PM  
Apr-05-22 12:14PM  
Mar-29-22 07:00AM  
Mar-24-22 07:00AM  
Mar-23-22 02:41PM  
Mar-10-22 05:01PM  
Mar-07-22 02:58PM  
Mar-04-22 05:45PM  
Feb-28-22 05:45PM  
Feb-17-22 10:52AM  
Feb-15-22 03:01PM  
Feb-01-22 09:38PM  
Jan-26-22 08:00AM  
Jan-20-22 05:36AM  
Jan-19-22 11:29AM  
Jan-18-22 07:00AM  
Jan-14-22 08:37AM  
Jan-13-22 05:45AM  
Jan-11-22 12:11PM  
Jan-05-22 08:00AM  
Jan-04-22 03:33PM  
Dec-23-21 06:35AM  
Dec-20-21 11:15AM  
Dec-17-21 06:35PM  
Dec-15-21 10:00AM  
Dec-12-21 05:04PM  
Dec-11-21 10:33AM  
Dec-09-21 07:38PM  
Nov-22-21 06:54AM  
Nov-17-21 02:33PM  
Nov-12-21 10:50AM  
Nov-08-21 05:30PM  
Nov-07-21 07:12AM  
Nov-05-21 08:25AM  
Nov-04-21 04:35PM  
Oct-27-21 03:04PM  
Oct-25-21 02:44PM  
Oct-21-21 09:59AM  
Oct-18-21 09:00AM  
Oct-08-21 04:54PM  
Sep-22-21 07:03AM  
Sep-21-21 04:15PM  
Sep-13-21 08:00AM  
Sep-08-21 11:30AM  
Sep-07-21 04:05PM  
Aug-13-21 10:50PM  
Aug-11-21 01:22AM  
Aug-09-21 04:04PM  
Aug-05-21 04:05PM  
Jul-28-21 03:03PM  
Jul-23-21 10:50PM  
Jul-21-21 05:00AM  
Jul-13-21 01:16PM  
Jul-10-21 09:01AM  
Jul-09-21 10:48AM  
Jul-04-21 07:49AM  
Jun-15-21 09:32AM  
Jun-11-21 10:50PM  
Jun-07-21 05:25PM  
Jun-04-21 11:31AM  
Jun-02-21 04:05PM  
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent -thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has collaboration and license agreements with Bristol-Myers Squibb, Regeneron Pharmaceuticals, Inc., Novartis Pharma AG, Orchard Therapeutics Limited, Medigene AG, Novo Nordisk A/S, Forty Seven, Inc., Gritstone Oncology, Inc., Magenta Therapeutics, Inc., the Seattle Children's Research Institute, University of North Carolina, and the Fred Hutchinson Cancer Research Center. bluebird bio, Inc. has a strategic alliance with National Resilience, Inc. to research, development, and delivery of cell therapies. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cole JasonChief Operating andJan 11Sale9.643,38732,659186,188Jan 12 09:15 PM
Leschly NickDirectorJan 11Sale9.645,06848,869281,330Jan 12 09:15 PM
Obenshain AndrewPresident and CEOJan 11Sale9.644,68345,156246,696Jan 12 09:15 PM
Whitten JessicaChief Accounting OfficerJan 11Sale9.642792,69049,413Jan 12 09:16 PM
Whitten JessicaChief Accounting OfficerJan 10Sale9.401301,22249,692Jan 12 09:16 PM
Obenshain AndrewPresident and CEOJan 10Sale9.363,04228,467251,379Jan 12 09:15 PM
Leschly NickDirectorJan 10Sale9.402,36922,274286,398Jan 12 09:15 PM
Cole JasonChief Operating andJan 10Sale9.401,58414,893189,575Jan 12 09:15 PM
Whitten JessicaChief Accounting OfficerJan 05Sale10.442,98431,14349,822Jan 07 04:28 PM
Obenshain AndrewPresident and CEODec 07Sale10.188328,469254,421Dec 09 04:51 PM
Obenshain AndrewPresident of SGDJun 04Sale30.7551115,71539,597Jun 08 04:26 PM